Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate in several December investor conferences to share commentary with investors around the Company’s pipeline, platform and business strategy.

Immuneering will present virtually at the following conferences:

Piper Sandler 33rd Annual Global Healthcare Conference (November 30 – December 2, 2021)

• Format: Fireside Chat and 1x1 Investor Meetings
• Fireside Chat Available On-Demand: Beginning November 22, 2021 at 10:00 am ET

4th Annual Evercore ISI HealthCONx Conference (November 30 – December 2, 2021)

• Format: Fireside Chat and 1x1 Investor Meetings
• Fireside Chat: December 1, 2021 from 2:15-2:35 pm ET

Oppenheimer AI Summit (December 7, 2021)

• Format: Company Presentation

The presentations from the Piper Sandler 33rd Annual Global Healthcare Conference and 4th Annual Evercore ISI HealthCONx Conference will be webcast live and available for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation                                        

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.        

Forward-Looking Statements

This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the offering filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.        

Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation
617-500-8080
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact:
Susan Noonan
Rx Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.